NCT01543568View on ClinicalTrials.gov

Study for Recalcitrant Age Related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Age Related Macular Degeneration
Interventions
DRUG

aflibercept 2.0 mg

Intravitreal aflibercept injection 2.0 mg

Trial Locations (1)

77030

Retina Consultants of Houston, Houston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

David M. Brown, M.D.

OTHER

NCT01543568 - Study for Recalcitrant Age Related Macular Degeneration | Biotech Hunter | Biotech Hunter